Therapeutic Response

EGFR p.T790M status confers therapeutic sensitivity to Aumolertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Aumseqa (aumolertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized aumolertinib as a monotherapy for treatment of adult patients with advanced EGFR T790M mutation-positive non-small cell lung cancer.